Reply from the authors [12]

Neurology

Volumn 66, Issue 11, 2006, Pages 1788-1789

  Frank, Samuel A ^a   Kieburtz, Karl ^a   Holloway, Robert ^a   Kim, Scott Y H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

HUMAN; INFORMED CONSENT; LETTER; MEDICAL ETHICS; PARKINSON DISEASE; PATIENT PARTICIPATION; PRIORITY JOURNAL; RISK ASSESSMENT; SURGICAL RISK;

EID: 33745662185     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000230564.67320.b1     Document Type: Letter

References (7)

1. Frank S, Kieburtz K, Holloway R, Kim SYH. What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology 2005;65:1101-1103.
2. Kim SYH, Frank S, Holloway R, Zimmerman C, Wilson R, Kieburtz K. Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers. Arch Neurol 2005;62:1357-1360.
3. Anderson FH, Lehrich JR. Lhermitte sign following head injury. Arch Neurol 1973;29:437-438.
4. Kordower JH, Palfi S, Chen E-Y, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46:419-424.
5. Landau WM. Artificial intelligence: the brain transplant cure for parkinsonism. Neurology 1990;40:733-740.
6. Landau WM. Tissue transplants for PD [special correspondence, reply to letters to the editor]. Neurology 1994;44:573-577.
7. Folkerth RD, Rudso R. Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Neurology 1996;46:1219-1225.